Abivax S.A.

NASDAQ:ABVX

Biotechnology

Healthcare
$83.83 -0.61%

-$0.62 today

Market cap
$7.34B
Beta
-0.20
P/E (TTM)
-18.1
EPS (TTM)
-$4.83
52W Low $5.69High $148.83

Volume 1.19M

Average 1.59M

ABVX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Abivax S.A.NASDAQ: ABVX

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development grows 51.0% year over year

Q2 FY2026 research & development of €58.34M rose 51.0% year over year. Over 3 fiscal years it compounded at +54.4% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
€58.34M— QoQ
Last fiscal yearDec 2025
€177.76M+21.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+51.0%——
1 year+21.3%——
3-year CAGR+54.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

EUR · from the income statement

Latest · FY2025
177.76M EUR
Year-over-year change
+21.3%
4-year CAGR
+38.9%

Research & Development vs competitors

How ABVX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +21.3% is the 5th highest of 11, against a peer median of +13.9%.
  • Over three fiscal years its annual growth of +54.4% compares with a peer median of +18.3%.
ABVX Competitors
Research & Development for ABVX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$497M USD+2.5%+22.0%424.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$331.95M USD+10.2%+18.6%47.3%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$259.72M USD+46.3%+43.1%287.0%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$255.99M USD+3.7%+29.7%117.9%
ABVXAbivax S.A.FY2025€177.76M EUR+21.3%+54.4%—
ANNXAnnexon, Inc.LTM Mar 2026$172.31M USD+17.5%+18.0%—
ANABAnaptysBio, Inc.LTM Mar 2026$128.65M USD-23.4%+15.3%55.4%
IVAInventiva S.A.FY2025€83.61M EUR-8.0%+11.4%1865.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$56.72M USD+60.6%-12.2%677.9%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$55.01M USD+74.4%+17.0%93235.6%
IMMXImmix Biopharma, Inc.LTM Mar 2026$20.26M USD+102.3%+57.1%—
Peer median (excluding ABVX) —+13.9%+18.3%355.9%

Competitors are the stored peer set for ABVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue45.52M50.76M000
Gross Profit(45.52M)(50.76M)000
Gross Margin—————
Research & Development47.78M48.3M103.18M146.53M177.76M
Selling, General & Admin5.58M7.49M28.82M38.9M72.87M
Operating Expenses(4.12M)14.07M127.38M172.98M246.06M
Depreciation & Amortization302K485K707K1.1M1.07M
EBITDA(38.59M)(53.32M)(133.21M)(162.71M)(300.7M)
EBITDA Margin—————
Operating Income(41.4M)(64.84M)(127.38M)(172.98M)(246.06M)
Operating Margin—————
Interest Income002.77M8.96M5.75M
Interest Expense3.56M6.94M13.83M12.43M28.48M
Other Income / Expenses(1.05M)4.1M(20.36M)(3.26M)(84.2M)
Income Before Tax(42.45M)(60.74M)(147.74M)(176.24M)(330.25M)
Pre-Tax Margin—————
Income Tax Expense00005.85M
Net Income(42.45M)(60.74M)(147.74M)(176.24M)(336.1M)
Net Margin—————
EPS (Basic)(2.75)(3.18)(3.43)(2.80)(4.65)
EPS (Diluted)(2.75)(3.18)(3.43)(2.80)(4.65)
Weighted Avg Shares15.46M19.09M43.07M63.05M69.53M
Weighted Avg Shares (Diluted)15.46M19.09M43.07M63.05M69.53M

Abivax S.A.

NASDAQ:ABVX

Intrinsic Alpha fair value

Locked

Current Price

$83.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.